It was a ‘mutual agreement,’ Novo says in a statement. A search for Fruergaard Jørgensen’s successor is ongoing.

The executive order instructs the FDA to expedite the approval process for domestic pharmaceutical manufacturing facilities.

Multinational pharmaceutical firms have been queuing up to announce multi-billion-dollar investments in US facilities. Roche, ...

INDIANAPOLIS — Eli Lilly and Company and Purdue University are keeping their partnership alive beyond it’s previously expected years. In an announcement made Friday, Lilly said they will invest up to ...

Karsten Munk Knudsen Thank you ... cash patients may prefer Lilly given a cheaper syringe vial strategy and [indiscernible] perception and efficacy safety is beginning to edge with Wegovy.

CFO Karsten Munk Knudsen said he expects Wegovy sales ... which was short of the projected 25% weight reduction. Eli Lilly released trial results for its latest weight-loss drug, retatrutide ...

Novo Nordisk shares jumped following stronger-than-expected first-quarter earnings, despite the company lowering its growth outlook for 2025 amid intensifying competition in the weight-loss drug ...

Novo Nordisk CFO Karsten Munk Knudsen speaks on Bloomberg Television about earnings, tariffs and the impact of compounding in the US, which he cites as a reason for the drugmaker's lower quarterly ...

Novo Nordisk Chief Financial Officer Karsten Munk Knudsen said in an interview it takes years ... His comments follow announcements by pharma companies including Novartis, Eli Lilly and Roche of huge ...

Novo Nordisk Chief Financial Officer Karsten Munk Knudsen said in an interview ... by pharma companies including Novartis, Eli Lilly and Roche of huge investments in U.S. manufacturing as the ...

Novo said it expects “a step up in the business that used to go to compounders” in the second half of the year, according to chief financial officer Karsten Munk Knudsen. Another potential ...